Stock ATOS ATOSSA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Atossa Therapeutics, Inc.

Equities

ATOS

US04962H5063

Market Closed - Nasdaq
Other stock markets
 16:00:00 2024-05-02 EDT 		5-day change 1st Jan Change
1.52 USD -0.65% Intraday chart for Atossa Therapeutics, Inc. 0.00% +72.73%
04-29 Atossa Therapeutics, Inc. Announces Expanded Research Agreement with Weill Cornell Medicine to Further Evaluate Synergy Between Antibody Drug Conjugates and (Z)-Endoxifen CI
04-15 Atossa Therapeutics and Quantum Leap Healthcare Collaborative Announces I-SPY 2 Clinical Trial to Evaluate (Z-Endoxifen in Combination with Abemaciclib (VERZENIO®?) in Women with ER+/HER2- Breast Cancer CI

Evolution of the average Target Price on Atossa Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

d9c2e4e3bd78804.DsqeB1k-htJe3cT2rucfk9JlN5fB0WcTfa4fLmsI2iE.Pb7cZiB3x4AKqJvB4LR41poCb9PwlgJ3DOVtZjNQo0la_9RvFnzymxzugQ~c99af935a2ee154d46e0a61c47c4bb7f

Analyst Recommendations on Atossa Therapeutics, Inc.

Atossa Therapeutics Rises After HC Wainwright Starts Coverage with Buy Rating MT
HC Wainwright Initiates Atossa Therapeutics With Buy Rating, Price Target is $4 MT
Cantor Fitzgerald Starts Atossa Therapeutics at Overweight With $5 Price Target MT
Maxim Group Adjusts Atossa Therapeutics Price Target to $4 From $7, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.52 USD
Average target price
4.667 USD
Spread / Average Target
+207.02%
High Price Target
6 USD
Spread / Highest target
+294.74%
Low Price Target
4 USD
Spread / Lowest Target
+163.16%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Atossa Therapeutics, Inc.

HC Wainwright
Cantor Fitzgerald
Maxim

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. ATOS Stock
  4. Consensus Atossa Therapeutics, Inc.